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Abstract
MYC deregulation is common in human cancer. IG-MYC translocations that are modeled in Eμ-
Myc mice occur in almost all cases of Burkitt lymphoma as well as in other B-cell
lymphoproliferative disorders. Deregulated expression of MYC results in increased mTORC1
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signaling. As tumors with mTORC1 activation are sensitive to mTORC1 inhibition, we used
everolimus, a potent and specific mTORC1 inhibitor, to test the requirement for mTORC1 in the
initiation and maintenance of Eμ-Myc lymphoma. Everolimus selectively cleared premalignant B-
cells from the bone marrow and spleen, restored a normal pattern of B-cell differentiation and
strongly protected against lymphoma development. Established Eμ-Myc lymphoma also regressed
after everolimus therapy. Therapeutic response correlated with a cellular senescence phenotype
and induction of p53 activity. Therefore mTORC1-dependent evasion of senescence is critical for
cellular transformation and tumor maintenance by MYC in B-lymphocytes.
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INTRODUCTION
Deregulated expression of the MYC proto-oncogene is one of the most ubiquitous
aberrations in human cancer. In up to 15% of cancers chromosome translocation or gene
amplification results in inappropriate expression of MYC. In a further 50% of cases, MYC
overexpression results from a variety of mechanisms including enhanced translation,
increased protein stability or disordered signaling upstream of MYC (1).
MYC is a bHLH-LZ transcription factor. In most instances, it acts by binding E-boxes and
recruiting transcriptional co-activators to regulatory promoter elements in target genes, but
MYC also binds MIZ1 to represses gene transcription at a small subset of targets. Despite
evidence from pre-clinical models that inactivating MYC translates into therapeutic benefits,
it has proven difficult to target MYC pharmacologically as it lacks a simple enzymatic
function that mediates its activity (2). However, oncogenic MYC gives rise to cellular
transformation through an aberrant transcriptional program and it is known that up to one
third of MYC target genes are regulators of energy metabolism and cell growth (3, 4).
The signal transduction molecule mTOR is also a critical mediator of cell growth. In the
mTORC1 multi-protein complex, mTOR associates with GβL, raptor, PRAS40 and deptor
to promote nutrient and growth factor dependent signaling (5). However, unlike MYC,
mTORC1 is readily amenable to allosteric inhibition by rapamycin and analogues including
everolimus (also known as RAD001 or Affinitor).
The Eμ-Myc transgenic mouse is a pre-clinical model that has been utilized extensively to
understand the sequelae of MYC deregulation (6). The transgene mimics the human t(8;14)
(q24;q32) that is characteristic of Burkitt lymphoma and juxtaposes MYC to the
immunoglobulin heavy chain enhancer leading to tissue-specific deregulation of MYC
expression. Expression of the Eμ-Myc transgene initially results in a premalignant
phenotype notable for abnormal B-cell development (7). The premalignant phase comprises
two stages. Firstly, there is polyclonal B-cell expansion with accumulation of
undifferentiated B-cells in haemopoietic organs (7, 8). During this phase, B-cells at
equivalent stages of development are larger than their counterparts in control mice and
exhibit increased protein synthesis, indicating that the failure of B-cells from Eμ-Myc mice
to differentiate is accompanied by deregulated cell growth (9). Subsequently, mice enter a
phase characterized by more rapid proliferation and turnover of B-cell precursors, increased
haemophagocytic activity and relative normalization of peripheral blood counts (8, 10).
During the premalignant phase unconstrained expression of MYC is counterbalanced by
activation of the Arf/p53 network and compensatory changes in Bcl2 family members
resulting in cell cycle arrest and cell death. Genetic deletion of Arf, p53 or Bim and
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overexpression of Bcl2 accelerates lymphomagenesis in Eμ-Myc mice (11–14).
Furthermore, p53 mutation or biallelic deletion of Arf coincides with outgrowth of mono- or
oligo-clonal malignant disease in half to two-thirds of spontaneously arising lymphomas
demonstrating that counter-regulatory measures must be disabled for malignant
transformation (12).
Anti-cancer strategies that target processes driven by the cell growth component of the MYC
transcriptome can be therapeutically beneficial. Blocking mTORC1 signal transduction
through co-transfection of TSC2 reduced colony formation driven by MYC (15) and
crossing mice heterozygous for ribosomal proteins with Eμ-Myc mice to restore ribosome
biogenesis and protein synthesis levels to those of normal B-cells increased the latency of
Eμ-Myc lymphomas (16). Furthermore, interventions to decrease transcription of the
ribosomal RNA genes have therapeutic efficacy in established Eμ-Myc lymphoma (17).
We hypothesized that administration of everolimus to Eμ-Myc mice would restore B-cell
differentiation and delay lymphoma onset. In fact, everolimus specifically rescued B-cell
development and conferred near-complete protection from malignant transformation
concomitant with enhanced senescence and clearance of pre-lymphomatous B-cells. In
addition, everolimus afforded significant control over malignant disease in a manner that
corresponded to senescence induction and the presence of a functional p53 response. These
data reveal that mTORC1 is necessary for MYC to bypass tumor suppression through
induction of cellular senescence.
RESULTS
mTORC1 is required for tumor initiation
To determine if mTORC1 activity was necessary for tumor initiation by MYC, we
randomized 4-week-old Eμ-Myc mice with no overt evidence of malignancy to receive
everolimus or the equivalent volume of a placebo (Supplementary Table S1). Mice
underwent weekly lymph node palpation for the duration of the study in addition to
peripheral blood monitoring after 2, 4 and 8 weeks of treatment. As expected, placebo-
treated mice developed fatal pre-B or B-cell leukemia/lymphoma (Fig. 1A and B) with a
median lymphoma free survival of 73 days (Fig. 1A). Overall, mTORC1 inhibition protected
strongly against malignant transformation with only four of thirty-three everolimus-treated
mice developing leukaemia/lymphoma after over 150 days of therapy (Fig. 1A and B). The
biology of tumors in everolimus-treated mice was also distinct. Tumors arising in placebo-
treated mice were approximately evenly distributed between B-cell (B220+/surface IgM
(sIgM)+/surface IgD(sIgD)low (53.8%)) and pre-B cell (B220+/sIgM-/sIgD- (46.2%))
tumors as expected from previous studies (18). In contrast, all tumors in everolimus-treated
mice had the pre-B immunophenotype (Supplementary Fig. S1A and B). Therefore
everolimus prevents Eμ-Myc lymphoma and treatment failure selects for lymphomas with a
pre-B phenotype.
Everolimus restores normal B cell development
Since there is an expanded polyclonal B-cell population in Eμ-Myc mice we examined
whether tumor prevention by everolimus was associated with reversal of this phenotype.
Immunophenotyping indicated that everolimus reduced the percentage of circulating B-cells
at the immature B (B220lo/sIgM+) and pre-B cell (B220lo/sIgM−) stages compared to
placebo (Supplementary Fig. S2A and B). Furthermore, absolute numbers of circulating B-
cells, and particularly undifferentiated B-cells, were reduced by mTORC1 inhibition to
levels equivalent to those in wild-type mice (Supplementary Fig. S2C-E). These data
indicate that mTORC1 inhibition rescued aberrant B-cell differentiation in Eμ-Myc mice.
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To thoroughly investigate the effects of everolimus on B-cell development, we next took
cohorts of 4-week-old Eμ-Myc mice and analyzed them after 2 weeks of therapy. We
observed that the spleen weight was restored to wild-type levels in association with a 50%
reduction in splenic B-cell numbers (Fig. 2A and B). Purified B220+ splenocytes in
everolimus-treated mice also had similar morphological characteristics to differentiated cells
observed in wild-type spleens with more condensed nuclear chromatin and greater
cytoplasmic pallor than B220+ splenocytes from placebo-treated mice (Fig. 2C). The mean
cell volume (MCV) of B220+ cells from everolimus treated mice was significantly reduced
in the spleen [placebo 264.9±6.1fl vs. everolimus 230.8±5.3fl (p=0.002)]. Furthermore,
analysis of B220+ B-cells demonstrated reduced percentages of the less differentiated sIgM
+/sIgDlo and sIgM-/sIgD- populations (Fig. 2D).
In the bone marrow, although overall cellularity was not significantly reduced by everolimus
therapy (Supplementary Fig. S3A), there was a greater than 50% reduction in the percentage
of B220+ lymphocytes (Supplemetary Fig. S3B). B220+ lymphocytes from the bone
marrow of everolimus-treated Eμ-Myc mice were also smaller than those from control mice
[MCV placebo 288.4±2.4fl vs. everolimus 266.9±3.9fl (p=0.002)]. Histology revealed
preserved trilineage hemopoiesis after everolimus therapy with loss of the expanded
population of B-lymphoblasts that remained apparent in the marrow of placebo-treated mice
(Supplementary Fig. S3C). Immunophenotyping demonstrated reduced proportions of both
B220+/sIgM- and B220+/sIgM+ B-cells (Supplementary Fig. S3D). These findings
demonstrate selective reduction of B-lymphocytes in the bone marrow after everolimus
therapy in the absence of non-specific myelosuppression.
To directly compare the effects of mTORC1 inhibition on B-cell populations from mice with
wild-type levels of MYC expression versus transgenic levels in Eμ-Myc mice we also
administered everolimus to wild-type mice. As in Eμ-Myc mice, we did not observe
myelosuppression in wild-type mice after everolimus therapy (Supplementary Fig. S4A–E).
However, unlike Eμ-Myc mice, B-cell numbers in the spleen and bone marrow of wild-type
mice were unchanged by everolimus treatment demonstrating the heightened sensitivity of
B-cells with oncogenic expression of MYC to mTORC1 inhibition (Supplementary Fig.
S5A and B). Taken altogether, the results suggest everolimus prevented tumor initiation
through preferential elimination of tumor-susceptible undifferentiated B-cell populations
from the spleen and bone marrow of Eμ-Myc mice.
MYC expression is maintained in the face of mTORC1 inhibition
To confirm the molecular inhibition of mTORC1 signaling in everolimus-treated mice we
monitored RPS6 phosphorylation. We observed an increase in phosphorylated RPS6 in
extracts from placebo-treated B-cells compared to wild-type controls corroborating the
established positive correlation between MYC levels and mTORC1 activity (15, 19) (Fig.
3A). In addition, phosphorylated RPS6 was reduced 24 hours after the last dose of
everolimus, confirming continued robust inhibition of mTORC1 in the target cell population
at trough drug levels. Given that rapamycin has been shown to regulate expression of MYC
at a post-transcriptional level (20, 21), we assayed expression of MYC protein and the MYC
transcriptional target genes ornithine decarboxylase 1 (ODC1) and upstream binding
transcription factor (UBTF)(Fig. 3B and C). Both MYC levels and activity were upregulated
in transgenic mice compared to wild-type controls and they remained elevated after
treatment with everolimus (Fig. 3A–C). Thus, mTORC1 inhibition prevented malignant
transformation despite continued MYC expression and function in premalignant cells.
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Everolimus has single agent activity against Eμ-Myc lymphoma
While short-term dosing with rapamycin lacked efficacy in treating established Eμ-Myc
tumors (19, 22), chronic regular administration of everolimus has not been assessed as a
therapeutic strategy. To investigate effects of longer-term mTORC1 inhibition on
established Eμ-Myc lymphoma, we generated tumors in host mice by transplantation of
spontaneously arising Eμ-Myc lymphomas. Everolimus treatment significantly improved
survival over placebo in all three lymphomas tested (Fig 4A and Supplementary Fig. S6A
and B). The extent of the effect ranged from a 1.3-fold increase to a doubling of overall
survival. For mice bearing the most everolimus responsive tumour, improved survival was
associated with reduced or absent lymphadenopathy, a reduction in the white cell count
(WCC) to normal or below normal levels (Fig. 4B) and minimal evidence of residual
circulating lymphoma (Supplementary Fig. S7A), consistent with disease remissions 24 days
after transplantation. Interestingly, by day 38, everolimus-treated mice displayed evidence of
disease relapse (Fig. 4B and Supplementary Fig S7A) where loss of disease control
coincided with outgrowth of a B220+/sIgM−/sIgD− tumor clone that comprised only a small
proportion the original tumor (Supplementary Fig. S7B and C). To further characterize these
tumors, we injected host mice with tumors harvested from mice that had failed everolimus
due to disease progression on therapy (EE) or equal passage everolimus-naïve (EN) tumors.
Everolimus again significantly delayed the onset of leukocytosis and improved overall
survival in drug-naïve tumors but failed to moderate leukocytosis or confer a survival
advantage over placebo in tumors re-exposed to everolimus (Fig. 4C and D). Thus relapse of
Eμ-Myc lymphoma resulted from selection for a tumor subpopulation with intrinsic
resistance to everolimus.
Everolimus activity does not correlate with apoptosis
As widespread apoptosis in response to chemo-radiotherapy is a feature of Eμ-Myc
lymphoma, we suspected that everolimus treatment might also trigger apoptosis to effect
tumor regression. Accordingly, mice with overt lymphoma were analyzed after a single dose
of everolimus for evidence of apoptosis over a 24-hour time period. Progressive diminution
in white cell counts of treated mice occurred (Fig. 5A) and corresponded with a G1 cell
cycle arrest in involved lymph nodes (Fig. 5B). However increased subG1 DNA
characteristic of apoptosis was minimal (Fig. 5B). To exclude the possibility of delayed
apoptosis we also carried out continuous daily dosing with everolimus: disease regression
occurred, followed by stabilization between day 2 and 7 of therapy and then relapse by day
11 (Supplementary Fig. S8A). As seen at the shorter time points, disease response during
ongoing everolimus administration was also associated with G1 arrest but again without
marked increases in subG1 DNA (Supplementary Fig. S8B). We then employed isogenic
tumor lines with constitutive BCL2 expression to examine whether functional apoptotic
machinery was required for everolimus sensitivity. Everolimus treatment conferred a
significant survival benefit over placebo in these tumor lines (median survival 13.5 days for
placebo and 19.0 days for everolimus, p=0.001) (Fig. 5C). Importantly, the survival benefit
of everolimus was maintained with enforced BCL2 expression (median survival 11.5 days
for placebo and 16.0 days for everolimus, p<0.0001) (Fig. 5D) suggesting functional
apoptotic networks are dispensable for everolimus activity. Thus everolimus administration
did not elicit an apoptotic response in Eμ-Myc lymphoma.
Everolimus induces cellular senescence
Analysis of tumor morphology to characterize responses to everolimus more thoroughly
revealed the presence of a mixed inflammatory cell infiltrate in involved lymph nodes that
was particularly prominent after 2, 4 and 7 days of therapy (Fig. 6A) coinciding with tumor
regression and disease stabilization (Supplementary Fig. S8A) and occurring in the absence
of histopathological changes in apoptosis. Given that cellular senescence has a prominent
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inflammatory component in in vivo tumor models (23), we investigated whether induction
of senescence might account for everolimus activity. Everolimus treatment was associated
with robust acquisition of senescence-associated β-galactosidase (SA-β-gal) activity in
tumors after 4 and 7 days of treatment that was lost upon disease relapse at day 11 indicating
that they no longer retain the capacity to undergo senescence (Fig. 6A and Supplementary
Fig. S9A). Furthermore, immunostaining to identify granulocytes and macrophages using
the markers Gr1 and F4/80 respectively confirmed an increase in infiltrating innate immune
cells capable of tumor clearance from day 2 (Fig. 6A and Supplementary Fig. S9B and C).
Interrogation of tumor samples by Western analysis obtained from everolimus-treated mice
showed p53/ARF induction in the context of persistent inhibition of RPS6 phosphorylation
(Fig. 6B). p21 levels were also upregulated, its expression coinciding with p53 serine 15
phosphorylation but preceding maximal p53 stabilization, thus possibly activated by low
levels of active p53 in this setting. Consistent with a senescence response, activation of the
senescence regulatory kinase p38MAPK occurred after 4 days of everolimus treatment (24).
We also observed an increase in H3K9 trimethylation (H3K9me3), a chromatin marker of
transcriptional silencing mechanistically linked to cellular senescence, likely through its role
in directing the silencing of E2F target genes (25, 26) (Fig. 6B). Thus, treatment of Eμ-Myc
lymphoma with everolimus was characterized by cell cycle arrest, SA-β-gal staining, an
innate immune response, and expression of tumor suppressor and senescence associated
genes consistent with oncogene-induced senescence as a mechanism for tumor clearance.
We hypothesized that a senescence mechanism was also operative during lymphoma
prevention by everolimus in premalignant Eμ-Myc mice. Therefore we treated four week
old mice with everolimus and analyzed them on day 4. In everolimus-treated mice
morphological analysis showed selective clearance of lymphoblasts known to be responsible
for expansion of the splenic red pulp in transgenic mice (18) and this was associated with
acquisition of SA-β-galactosidase activity (Fig. 6C and Supplementary Fig. S10A). We also
observed a gene expression profile, including increased expression of transcripts encoding
the extracellular signaling molecules ICAM1, IGFBP7 and IL6, that is reflective of a
senescence response in B220+ but not B220- cell populations in bone marrow isolated from
mice treated for 4 days with everolimus (Supplementary Fig. S10B). Overall, these data in
the prevention model corroborate those in the established Eμ-Myc tumor model and provide
further evidence that activity of mTORC1 is required for avoidance of MYC-induced
senescence in B-lymphocytes.
Tumor response to everolimus requires an operative senescence response and a
functional p53 pathway
There was a robust temporal relationship between loss of response to everolimus and intra-
tumoral selection for cells incapable of undergoing cellular senescence (Fig. 6A and
Supplementary Fig. S9, compare day 4, 7 with day 11). In murine models, p53 is widely
regarded as a key mediator of senescence and in Eμ-Myc lymphoma p53 mutation is a well-
characterized secondary genetic alteration (12). Therefore we examined whether everolimus
resistance was associated with loss of p53 function. Given that etoposide sensitivity is a
known indicator of p53 function (27, 28), we challenged everolimus-resistant tumors with
etoposide. While mice transplanted with everolimus-naïve (EN) tumors showed improved
survival with etoposide treatment, everolimus-exposed (EE) tumors displayed markedly
compromised etoposide sensitivity (Fig. 7A and B). To genetically interrogate the
requirement for p53 function in everolimus responsiveness, tumors derived from Eμ-Myc
mice with either genetic deletion of p53 or characterized by spontaneous p53 mutation were
transplanted and mice were monitored for survival. The average survival advantage
conferred by everolimus over placebo was 1.1-fold for lymphomas with homozygous
deletion or mutation of p53 (Fig. 7C–D, Supplementary Fig. S11) compared to 1.7-fold for
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the panel of three p53 wild-type lymphomas we screened initially (Fig. 4A, Supplementary
Fig. S6A and B). Thus, the effectiveness of everolimus therapy was diminished in Eμ-Myc
lymphomas where p53 was deleted or p53 signaling was dysfunctional.
DISCUSSION
Rapamycin, and rapamycin analogues are potent and selective inhibitors of mTORC1, with
on-target activity at low nanomolar concentrations and no off-target kinase inhibition at
levels below 1μM (29). Everolimus improves clinical outcomes and is approved for use in
the treatment of metastatic renal cell carcinoma (30) and subependymal giant cell
astrocytomas associated with tuberous sclerosis (31). mTORC1 inhibitors are currently
being assessed in clinical trials in a variety of other human cancers. Therefore, mTORC1
inhibitor drugs serve both as tools that allow us to address important biological questions
about mTORC1 loss of function and as validated cancer therapeutics.
MYC transcriptionally regulates several components of the mTOR pathway and there is a
positive relationship between expression of MYC and mTORC1 activity. We found that
mTORC1 activity is increased in premalignant B-cells isolated from Eμ-Myc mice and we
have shown that mTORC1 activity in this model can be safely and effectively inhibited by
once-daily dosing with everolimus. Our results indicate therapeutic intervention to inhibit
mTORC1 during the premalignant phase acts as a powerful barrier to the acquisition of
additional genetic hits that facilitate malignant transformation.
Transcripts that encode MYC have a complex 5′ UTR rendering MYC vulnerable to post-
transcriptional inhibition by mTORC1 inhibition and post-transcriptional modification of
MYC expression can influence MYC-driven phenotypes under some experimental
conditions (20, 21). However, in this study there was continued expression and
transcriptional activity of MYC in B-lymphocytes from transgenic mice treated with
everolimus. This data is consistent with a model in which everolimus does not mediate its
effects by reducing MYC function but rather acts via a parallel pathway or downstream of
MYC to determine the cellular response to oncogenic MYC expression.
We found that everolimus improved the survival of mice transplanted with spontaneously
arising Eμ-Myc lymphomas that were wild-type for p53. Tumor regression in response to
mTORC1 inhibition was not associated with apoptosis. Furthermore, everolimus sensitivity
persisted in tumors with enforced expression of BCL2. In keeping with our findings,
everolimus did not induce apoptosis of B-ALL cells in xenograft experiments (32). It is
known that the apoptotic response to rapamycin in Eμ-Myc lymphoma can be heightened by
interventions that activate signaling upstream of mTORC1 such as expression of
myristolated AKT, deletion of PTEN or loss of TSC2 (19, 22, 33). Notably, in our studies
we did not hyperactivate AKT and observed cellular senescence rather than apoptotic cell
death after mTORC1 inhibition. Thus, mTORC1 signal intensity may determine whether
tumor cells undergo apoptosis or senescence in response to mTORC1 inhibition.
Oncogene-induced senescence is thought to function as a safeguard that premalignant cells
must circumvent in order to undergo malignant transformation. Accordingly, as malignant
potential evolves, the risk of dysfunction or inactivation of cellular senescence programs
increases. The effects of mTORC1 inhibition in premalignant Eμ-Myc mice, where
senescence pathways are expected to be intact, were robust and highly reproducible.
However, in malignant disease where tumor biology is modified by a spectrum of distinct
secondary genetic events, the activity of everolimus was more variable and response was
associated with outgrowth of resistant clones. In premalignant mice, pre-existing occult
malignancy with intrinsic everolimus resistance probably accounts for the early overlap in
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survival curves in placebo- and drug-treated cohorts (Fig 1A). These results suggest that the
nature of the additional genetic events that coincide with tumor initiation and progression
strongly influences everolimus sensitivity.
Identification of senescence relies on the presence of senescence-associated β-galactosidase
together with a host of additional markers, many of which are known to be context
dependent (34). Eμ-Myc lymphomas treated with everolimus had numerous features
characteristic of senescence including staining for senescence-associated β-galactosidase,
phosphorylation and stabilization of p53, upregulation of p21 and p19Arf, increased histone
H3K9 trimethylation (H3K9me3), G1 cell cycle arrest, activation of p38MAPK and markers
of tumor inflammation. Indeed, many regard the sustained and irreversible cessation of
proliferation as a fundamental characteristic of senescence. Of all the senescence indicators
present in our study, perhaps the best testament to the irreversibility of the everolimus effect
is the long-term protection it affords pre-lymphomatous mice from malignant
transformation.
The importance of oncogene-induced senescence in Eμ-Myc lymphoma has been
highlighted by recent papers showing that senescence abrogation through genetic deletion of
the histone methyltransferase Suv39h1 greatly reduced the tumor latency of Eμ-Myc
lymphomas (26) and senescence induction by genetic deletion of CDK2 delays
lymphomagenesis in Eμ-Myc mice (35). Our work critically extends these observations by
demonstrating that the route to malignant transformation through suppressed senescence can
be selectively targeted pharmacologically to realize biologically significant improvements in
survival.
The TGF-β pathway has been linked to senescence induced by MYC. Van Riggelen et al
reported that senescence occurring in T cell lymphomas after MYC inactivation requires
TGF-β signaling and that the Miz1-mediated effects of MYC negatively regulate senescence
in response to TGF-β (36). There is also complex interplay between the tumor and the host
immune system during senescence. In a mouse model of T-cell acute lymphoblastic
lymphoma, the senescence and clearance of malignant cells after tetracycline-mediated
suppression of MYC expression was impaired in the absence of CD4+ T-cells (37).
Reimann et al identified two pathways to MYC-induced senescence in Eμ-Myc lymphomas:
a relatively weak cell autonomous pathway and a stronger non-cell autonomous pathway
that required secretion of TGF-β by activated macrophages in the tumor stroma (26). The
senescence response was dependent on Suv39h1 activity as monitored by the repressive
chromatin mark, H3K9me3. Our studies demonstrated that macrophage recruitment and
H3K9me3 are features of the senescence response induced by everolimus. In addition, we
did not observe markers of senescence after treatment of Eμ-Myc lymphoma cell lines with
everolimus in vitro (data not shown) suggesting that non-malignant immune cells in the
tumor stroma make a significant contribution to the senescence triggered by mTORC1
inhibition in this model.
With respect to other forms of oncogene-induced senescence, there is a growing body of
evidence to support the contention that PI3K/AKT/mTOR signaling is inhibitory to
senescence triggered by deregulation of the RAS pathway. In the inherited condition
neurofibromatosis type 1, inactivating mutations of the NF1 gene lead to RAS activation;
within benign neurofibromas from these patients, generation of a negative feedback loop
that downregulates P13K/AKT signaling triggers senescence (38). A more recent study
using a mouse model of pancreatic cancer showed that RAS-induced senescence was
suppressed by activating the PI3K pathway via PTEN deletion and that loss of PTEN
accelerated tumorogenesis in a gene-dosage dependent manner. Rapamycin administration
rescued senescence suggesting that signaling through mTORC1 was necessary to restrain
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RAS-induced senescence in premalignant lesions in the pancreas (39). Likewise, in human
melanocytes an shRNA that reduced expression of PTEN prevented senescence provoked by
the oncogene BRAFV600E (40). Our study is the first to demonstrate that mTORC1
inhibitors can exert their anti-cancer activity by provoking senescence induced by the MYC
oncogene suggesting that inhibition of senescence by PI3K/AKT/mTOR signaling may
occur in oncogene-induced senescence other than that due to oncogenic RAS signaling.
mTORC1 inhibition can prevent or delay the onset of malignancy in other cancer-prone
mice (41–46). Whether cellular senescence occurs in other mouse models where cancer is
prevented by mTORC1 inhibitors is unclear.
Growing understanding of the role senescence plays in cancer has spurred interest in the
idea of harnessing senescence induction for therapeutic benefit. Our study serves as proof of
principle that targeted therapy can bring about tumor regression by activating senescence. At
the same time, our data illustrate some potential pitfalls of this approach. In established
lymphoma, the response to everolimus was not sustained due to strong selective pressure
favoring pre-existing senescence-defective tumor subpopulations. Thus, future strategies
will need to anticipate and avoid outgrowth of evolved clones with intrinsic drug resistance
due to failure to senesce if we are to leverage such therapies for maximal clinical gain.
There is a lack of consensus in the literature about whether a functional p53 pathway is
required for the anti-cancer activity of mTORC1 inhibitors. Studies in myeloma (47), breast
(48) and ovarian (49) cancer cells in vitro and in ovarian cancer xenografts (50) suggests
that tumors dependent on AKT signaling for survival respond to mTORC1 inhibition
irrespective of p53 status. In contrast, Beuvink et al (51) showed that RNAi knockdown of
p53 abolished synergistic killing of A549 lung cancer cell lines by RAD001 and cisplatin,
and Wendel et al (22) demonstrated p53-dependent resistance to rapamycin in Eμ-
Myc;PTEN+/− lymphomas. Given the clinical implications, we made it a priority to
establish the p53 dependence of the everolimus response in Eμ-Myc lymphomas.
In the current study we found that Eμ-Myc lymphomas generated on the background of p53
genetic loss of function display intrinsic everolimus resistance (Fig. 7C-D) demonstrating
that a therapeutic response to everolimus requires functional p53. Consistent with this,
resistance to everolimus coincided with the outgrowth of resistant clones that are defective
for the p53 pathway. Surprisingly, although etoposide sensitivity is a reliable indicator of
intact p53 function, sequencing of p53 exons did not identify any somatic mutations to
account for the loss of etoposide sensitivity that tracked with everolimus resistance (data not
shown). Thus, loss of p53 function is likely to be mediated through mechanisms other than
mutations in the coding region of p53 as previously reported in malignant disease (52).
Interestingly, when we treat Eμ-Myc mice with CX-5461, a small molecule inhibitor of Pol
I transcription and the ribosomal RNA synthesis pathway that is under the direct control of
mTOR, animal survival is significantly improved in a p53-dependent manner. Likewise,
sequencing of p53 exons in CX-5461 resistant clones failed to uncover the expected p53
mutations, suggesting that, in this model, drug pressure on a functional p53 pathway in
response to inhibition of growth and translation is borne out via molecular lesions other than
p53 itself (data not shown) (17). Greater understanding of the factors that mediate
everolimus resistance may be of universal benefit by identifying ways to improve the
clinical performance of mTORC1 inhibitors through the use of rational drug combinations.
One potential approach to combat the outgrowth of resistant clones is use of everolimus in
combination with drugs that are known to have p53-independent cytotoxicity, such as
vorinostat (53). While overall the survival advantage conferred by wild-type p53 over
deleted or mutated p53 was robust (an average of 12.8 compared to 2.5 days, see Fig. 4A,
Supplementary Fig. S6 and Fig. 7C-D, Supplementary Fig. S11, respectively), it is also of
interest that there was variability in the observed everolimus response amongst the p53 wild-
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type tumors. This suggests that additional factors, such as cooperating genetic lesions that
impact on disease aggression or influence interaction with host stromal cells, have a role to
play in determining the relative everolimus sensitivity of those tumors with wild-type p53.
Everolimus is currently undergoing testing in clinical trials in mantle cell lymphoma and
diffuse large B-cell lymphoma. MYC translocations and p53 mutation/deletion are known to
occur in both of these tumor types (54, 55). Furthermore, a common criterion for patient
inclusion in such clinical trials is failed therapy with standard first-line treatment regimens
that incorporate multi-agent chemotherapy and it is this particular cohort that may be
enriched for patients with tumors that have lost functional p53 and/or have a rearrangement
of MYC. Our findings are of immediate clinical relevance as they suggest that MYC
rearrangement and p53 status may constitute predictive biomarkers for response to
everolimus in B-cell lymphomas.
MATERIALS AND METHODS
Experimental animals
Eμ-Myc C57BL/6 transgenic mice were generated as described previously (6). Six to eight
week old C57BL/6J male mice were used as recipient syngeneic mice for tumor
transplantation studies. Distressed mice identified by weight loss, ruffled coats, dyspnoea,
paralysis, immobility or hunched posture were bled, humanely euthanased and autopsied.
All mouse experiments were performed in accordance with guidelines administered by the
Peter MacCallum Cancer Centre Experimental Animal Ethics Committee.
Eμ-Myc lymphoma prevention
Everolimus (RAD001) and placebo formulations were provided by Novartis (Basel,
Switzerland). Four to five week old Eμ-Myc mice were randomized to receive everolimus
5mg/kg (n=33) or the equivalent volume by weight (10μL/g body weight) of placebo (n=34)
by oral gavage, once daily 6 days each week on an ongoing basis. Mice were bled and
palpated after randomization to exclude overt lymphoma prior to therapy and inspected daily
for evidence of morbidity thereafter. From randomization, mice were weighed and
underwent lymph node palpation once a week. Peripheral blood B-cell differentiation was
assessed at randomization and after 2, 4 and 8 weeks. Wild-type (WT) mice (n=8) assigned
as matched littermate controls were weighed weekly and bled at the same time points.
Endpoints were time to lymphoma development and time to sacrifice.
Eμ-Myc lymphoma transplantation
2.5×105 cryopreserved cells were thawed and resuspended in sterile PBS before introduction
into syngeneic recipient mice by tail vein injection. Mice were dosed with everolimus or
placebo as described above. Lymphadenopathy was assessed by weekly palpation and
peripheral blood lymphocytosis was monitored by serial blood tests. Endpoints were
peripheral blood lymphoma burden and time to sacrifice. Lymphomas were determined as
wild-type for p53 via sequencing or mutant after assessment of protein molecular weight via
western blotting, in addition to exhibiting resistance to etoposide (17, 56).
Blood sampling
Seventy-five to one hundred microliters of blood was obtained from the retro-orbital sinus.
White cell counts (WCC) were measured using an Advia 120 automated hematology
analyzer (Bayer Diagnostics, Tarrytown, NY).
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B-cell isolation
Cells suspended at 107/100μL were incubated with biotinylated rat anti-mouse B220
antibody (BD Pharmingen, San Diego, CA) followed by washing and resuspension in 80μL
of MACS buffer/107 cells. Twenty microliters of goat anti-rat IgG microbeads (Miltenyi
Biotech, Bergisch Gladbach, Germany) was added to each sample and the cells were
incubated for 15 minutes. Cells were labeled with streptavidin conjugated PE (BD
Pharmingen) and resuspended in buffer prior to magnetic separation using the autoMACs
(Miltenyi Biotec) POSSEL program. Cells were deemed to be of adequate purity if greater
than 90% were B220 positive.
Immunophenotyping
Single cell suspensions were labeled with APC-conjugated rat anti-mouse B220 (CD45R)
(eBioscience, San Diego, CA), FITC-conjugated rat anti-mouse IgM and PE-conjugated rat
anti-mouse IgD (BD Pharmingen) or APC-conjugated rat anti-mouse B220, FITC-
conjugated rat anti-mouse CD24 (BD Pharmingen) and PE-conjugated rat anti-mouse CD43
(BD Pharmingen), washed then resuspended in buffer containing 2μM FluoroGold
(hydroxystilbamidine, Molecular Probes, Invitrogen, Carlsbad, CA) prior to data collection
on an LSR-II flow cytometer and analysis using FCS Express software.
Immunophenotyping was used to stage B-cells developmentally based on the model of
Hardy et al (57) as adapted by Iritani and Eisenman (9).
Western blotting
Equal amounts (20–50μg) of protein lysates were separated by SDS-PAGE as described
previously (21). Separated proteins were transferred to Immobilon-P membranes (Millipore,
Billerica, MA), and probed with antisera prior to detection by enhanced chemiluminescence
and autoradiography. Antibodies used were: c-MYC (9402), RPS6 5G10 (2217), P-RPS6
S240/244 (2215), P-p53 S15 (9284), p38 MAPK (9212), P-p38 MAPK (9211) (all obtained
from Cell Signaling Technology, Danvers, MA), actin C4 (69100, MP Biomedicals, Solon,
OH), p19 ARF 5-C3-1 (sc-32748), p21 C-19, (sc-397) (both obtained from Santa Cruz
Biotechnology, Santa Cruz, CA), p53 (NCL-p53-505, Novocastra, Leica Microsystems,
Wetzlar, Germany) and H3K9me3 (ab8898, Abcam, Cambridge, MA). Full-length blots are
presented in Supplementary Fig. S12A-M.
Quantitative real-time PCR
RNA was isolated by direct cell lysis using Trizol reagent according to the manufacturers
instructions (Invitrogen). Equal starting amounts of RNA were DNase treated at 37°C for 15
minutes and reverse transcribed by Superscript III (Invitrogen) using random hexamers
(Promega, Madison, WI). Eighteen microliters of master mix containing cDNA and SYBR
Green was added to 2μL of a 100μM forward and reverse primer. PCR and detection was
performed in an ABI prism 7000 thermocyler (Applied Biosystems, Warrington, UK).
Results were quantitated using the ΔΔCT method (58). Primer sequences are provided
(Supplementary Table S2) or have been described previously (21).
Cell cycle analysis
5×105 cells were fixed by the dropwise addition of 4.5mL of ice-cold 95% ethanol during
slow vortexing and placed at 4°C for 24 hours. Washed cells were resuspended in 300μL of
PBS-2% FBS containing 10μg/mL of propidium iodide and 250μg/ml RNAase A for 30
minutes prior to analysis. 5,000 single cell events were captured using a flow cytometer and
analyzed using Modfit software (Verity Software House).
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Immunofluorescence
4μm fresh frozen sections were fixed in ice-cold acetone, washed and incubated with rat
anti-mouse Gr1 (BD Pharmingen) and F4/80 (AbD Serotec, Oxford, UK) antibodies,
incubated with goat anti-rat Alexa 647 secondary antibody (Invitrogen) and mounted in
Prolong Gold with DAPI (Invitrogen). Images were acquired using an Olympus BX-51
fluorescent microscope and analyzed using SPOT advanced Software (Diagnostic
Instruments).
Senescence β-galactosidase staining
8μm sections were cut from samples embedded in Tissue-Tek OCT (Sakura Finetek) and
stained using the Senescence β-galactosidase staining kit (Cell Signaling, Beverly, MA)
according to the manufacturer’s instructions.
Statistical Analysis
Survival curves were plotted using the Kaplan-Meier method. The log-rank test was used to
assess differences and nominal p values were calculated.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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SIGNIFICANCE
this work provides novel insights into the requirements for MYC-induced oncogenesis by
showing that mTORC1 activity is necessary to bypass senescence during transformation
of B-lymphocytes. Furthermore, tumor eradication through senescence elicited by
targeted inhibition of mTORC1 identifies a previously uncharacterized mechanism
responsible for significant anti-cancer activity of rapamycin analogues and serves as
proof of concept that senescence can be harnessed for therapeutic benefit.
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Figure 1. mTORC1 is required for malignant transformation in the Eμ-Myc model
(A) Lymphoma-free survival curves for Eμ-Myc mice treated with placebo (n=34) and
everolimus (n=33). Median survival was 73 days in the placebo arm and was not reached in
the everolimus treatment arm (p=0.0004). (B) Wild-type littermate control mice (WT) (n=8),
Eμ-Myc mice treated with placebo (P) (n=34) and with everolimus (E) (n=33) were bled at
4–5 weeks of age (t=0) and after 2, 4 and 8 weeks. White cell counts of individual mice
from each group are shown. Horizontal bars represent mean values.
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Figure 2. B-cell precursors in the spleen of Eμ-Myc mice are reduced by mTORC1 inhibition
6–7 week old wild-type littermate control mice (WT) (n=5), Eμ-Myc mice treated with
placebo (P) for 2 weeks (n=5) and Eμ-Myc mice treated with everolimus (E) for 2 weeks
(n=7) were analyzed. (A) Average spleen weight (P vs E, p=0.001). (B) Percent B220+
splenocytes (P vs E, p=0.001). (C) May Grunwald-Giemsa stained cytospin preparations of
unsorted splenocytes (top) and purified B220+ cells (bottom) in a representative mouse from
each group. (D) FACS plots showing surface expression of IgM and IgD in B220+ gated
splenocytes for a representative mouse from each group. Error bars represent the SEM. p
values were generated using a Student’s unpaired 2-tailed t-test, *=p<0.05.
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Figure 3. Treatment of Eμ-Myc mice with everolimus does not reduce MYC expression or
activity in vivo
Age-matched wild-type littermate control mice (WT), premalignant Eμ-Myc mice treated
with placebo for 2 weeks and premalignant Eμ-Myc mice treated with everolimus for 2
weeks were sacrificed and purified B-cells were obtained from the bone marrow and spleen.
(A) Expression of MYC and P-RPS6 by Western blotting in purified B220+ B-cells from the
bone marrow (left) and spleen (right) of a WT, a placebo-treated transgenic mouse (TG) and
three everolimus-treated TG mice. Actin was used as a loading control. Full-length blots are
presented in Supplementary Fig. S12. Transcript abundance by qRT-PCR of the MYC target
genes ODC1, and UBTF in B220+ cells from the bone marrow (B) and spleen (C) of WT
(n=3), placebo-treated transgenic (n=5) and everolimus-treated transgenic mice (n=7).
mRNA expression levels were corrected for the expression of ubiquitin B and normalized to
expression in WT controls. Data shown is the average ± SEM.
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Figure 4. Everolimus-induced tumor regression and resistance in established Eμ-Myc lymphoma
(A and B) Syngeneic mice were injected with Eμ-Myc lymphoma cells (tumor#299).
Dosing with placebo (P) or everolimus (E) commenced on day 14 with the onset of overt
malignancy (n=5 mice/group). Surviving mice were bled 14, 24 and 38 days after tail vein
injection of tumor cells. (A) Survival curves. Median survival was 25 days for placebo and
53 days for everolimus (p=0.003). (B) White cell counts of mice 14, 24 and 38 days after
tumor injection. (C and D) Syngeneic mice were injected with everolimus-naïve (EN) Eμ-
Myc lymphoma cells (tumor#299) or equal-passage cells previously exposed to everolimus
(EE). Dosing with placebo or everolimus started 72 hours after injection (n=10 mice/group).
(C) White cell counts 10 days after transplantation (EN tumor: placebo vs everolimus,
p<0.001, EE tumor: placebo vs everolimus, p=0.07). Error bars represent the SEM. p values
were generated using a Student’s unpaired 2-tailed t-test, *=p<0.05, NS=not significant. (D)
Survival curves. For EN tumor the median survival was 22 days for placebo and 33 days for
everolimus. For EE tumor the median survival was 20 days for placebo and 22 days for
everolimus.
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Figure 5. Everolimus does not act by apoptosis
(A and B) Syngeneic mice were injected with Eμ-Myc lymphoma cells (tumor#299),
treated with a single dose of everolimus after the development of overt malignancy and
analyzed 0, 6 and 24 hours (H) after treatment (n=4 mice per group). (A) White cell counts
(B) Representative DNA histograms (top panel) and the average percentage of cells in each
phase of the cell cycle (bottom panel) in fixed propidium-iodide (PI) stained tumors. (C and
D) Matched isogenic Eμ-Myc lymphoma cells (tumor#107 or #4242) transduced with
MSCV or MSCV Bcl2 were injected into syngeneic recipient mice. Dosing with placebo or
everolimus was started 72 hours after injection. (C) Survival curves for everolimus- and
placebo-treated mice bearing tumors expressing MSCV (n=10 mice per group). Median
survival was 13.5 days for placebo and 19 days for everolimus (p=0.001). (D) Survival
curves for everolimus- and placebo-treated tumors expressing Bcl2 (n=10 mice per group).
Median survival was 11.5 days for placebo and 16 days for everolimus (p<0.001). Median
survival in everolimus-treated mice was increased 1.41-fold in tumors expressing MSCV
and 1.39-fold in tumors expressing Bcl2.
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Figure 6. mTORC1 is required to prevent cellular senescence
(A and B) Syngeneic mice were injected with Eμ-Myc lymphoma cells (tumor#299),
treated once daily with everolimus (E) after the development of overt malignancy and
sacrificed after 0, 2, 4, 7 and 11 days of therapy (n=4 mice per group). (A) Sections from
lymph nodes of untreated mice and mice sacrificed 2, 4, 7 and 11 days after chronic daily
dosing with everolimus were stained with H&E, SA-β-gal, anti-Gr1 and anti-F4/80. (B)
Expression of phospho- (P-S15 p53) and total p53, p21, p19ARF, phospho- (P-p38 MAPK)
and total p38 MAPK, phospho- (P-RPS6) and total RPS6 and H3K9me3 in tumor lysates by
Western blotting. Actin was used as a loading control. Full-length blots are presented in
Supplementary Fig. S12. (C) 4 week old Eμ-Myc mice were treated with daily placebo
(n=4) or everolimus (n=4) and sacrificed after 4 days. Splenic sections stained with H&E
(top), or SA-β-gal (bottom).
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Figure 7. Everolimus resistance is associated with loss of functional p53
(A and B) Syngeneic mice were injected with everolimus-naïve (EN) Eμ-Myc lymphoma
cells (tumor#299) or equal-passage cells previously exposed to everolimus (EE). After the
development of overt malignancy on day 14, mice were treated with placebo or etoposide
(25mg/kg ip) on 3 consecutive days (n=7 mice per group). Surviving mice were rebled on
day 28. (A) White cell counts of mice prior to therapy with etoposide at 14 days (D14) post
tail vein injection (TVI) and 14 days after etoposide (D28) (p<0.001 for EN vs EE tumors
treated with etoposide at D28), *=p<0.05. (B) Survival curves. Median survival was 24 days
and 25 days for placebo-treated EE and EN tumors respectively and 35 days and 54.5 days
for etoposide-treated EE and EN tumors (p=0.03 for EN vs EE tumors treated with
etoposide). (C and D) Syngeneic mice were injected with lymphoma cells (tumor#3391 or
tumor #3239) derived from spontaneously arising tumors in Eμ-Myc;p53−/− mice. Dosing
with placebo or everolimus was started 72 hours after injection. (C) White cell counts of
mice measured 10 days after commencement of therapy (top panel), (placebo vs everolimus,
p=0.26). (D) Survival curves for everolimus-treated and placebo-treated mice (bottom
panel). Median survival was 17 days in the placebo group and 18 days in the everolimus
group (n=10 mice per group). Error bars represent the SEM. p values were generated using a
Student’s unpaired 2-tailed t-test, *=p<0.05.
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